Towards a sustainable system of drug development

Ellen H.M. Moors, Adam F. Cohen, Huub Schellekens

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Drug development has become the exclusive activity of large pharmaceutical companies. However, the output of new drugs has been decreasing for the past decade and the prices of new drugs have risen steadily, leading to access problems for many patients. By analyzing the history of drug development and the pharmaceutical industry, we identified the main factors causing this system failure. Although many solutions have been suggested to fix the drug development system, we believe that a combination of reforms of the regulatory and patent systems is necessary to make drug development sustainable. These reforms must be combined with a larger, open-access role for public research institutes in the discovery, clinical evaluation and safety evaluation of new drugs.
Original languageEnglish
Pages (from-to)1711-1720
Number of pages10
JournalDrug Discovery Today
Volume19
Issue number11
DOIs
Publication statusPublished - 1 Nov 2014

Keywords

  • generic drug
  • new drug
  • cost effectiveness analysis
  • drug approval
  • drug development
  • drug industry
  • drug manufacture
  • drug marketing
  • drug safety
  • drug screening
  • drug surveillance program
  • human
  • industrial production
  • mergers and acquisitions
  • patent
  • public-private partnership
  • reimbursement
  • review

Fingerprint

Dive into the research topics of 'Towards a sustainable system of drug development'. Together they form a unique fingerprint.

Cite this